Insider Buying: enVVeno Medical Corporation (NASDAQ:NVNO) Director Acquires $10,290.00 in Stock

enVVeno Medical Corporation (NASDAQ:NVNO) Director Robert Gray acquired 3,500 shares of the company’s stock in a transaction on Tuesday, December 31st. The stock was bought at an average cost of $2.94 per share, with a total value of $10,290.00. Following the completion of the acquisition, the director now directly owns 11,155 shares in the company, valued at approximately $32,795.70. This represents a 45.72 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

enVVeno Medical Stock Up 9.4 %

NVNO stock opened at $3.36 on Friday. enVVeno Medical Corporation has a 52 week low of $2.45 and a 52 week high of $6.97. The business has a 50-day simple moving average of $3.16 and a 200 day simple moving average of $4.24. The company has a market cap of $58.93 million, a PE ratio of -2.60 and a beta of 1.22.

enVVeno Medical (NASDAQ:NVNO) last issued its earnings results on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, analysts anticipate that enVVeno Medical Corporation will post -1.3 EPS for the current fiscal year.

Institutional Investors Weigh In On enVVeno Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Hohimer Wealth Management LLC acquired a new position in shares of enVVeno Medical during the 3rd quarter worth $286,000. Maven Securities LTD bought a new position in enVVeno Medical in the third quarter valued at about $295,000. Westside Investment Management Inc. raised its stake in enVVeno Medical by 128.0% during the third quarter. Westside Investment Management Inc. now owns 88,375 shares of the company’s stock worth $297,000 after acquiring an additional 49,613 shares in the last quarter. Corsair Capital Management L.P. bought a new position in shares of enVVeno Medical in the third quarter worth about $390,000. Finally, Geode Capital Management LLC boosted its stake in shares of enVVeno Medical by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after purchasing an additional 10,902 shares in the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).